{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-049571","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.689738+00:00","generated_at":"2026-05-29T04:52:12.200433+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections","bullets":["VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.","Seed round term sheet (non-binding) for up to $3M in three tranches at valuations tied to Series A; 5,278 Class B shares issued.","University of Miami (Bascom Palmer) receives minority equity; 5% ownership until $2M qualified investment.","Initial directors: Webster Bailey, Jack Lacey, Ed Pershing (Chair). Officers: Dominic Rodrigues (Acting CEO), Heather Raines (Acting CFO).","RB PDAT tested in >500 patients globally; targeting $60B ophthalmic market with broad-spectrum antimicrobial therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-049571","json":"https://secwatch.observer/filing/0001493152-24-049571.json","markdown":"https://secwatch.observer/filing/0001493152-24-049571.md","text":"https://secwatch.observer/filing/0001493152-24-049571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224049571/0001493152-24-049571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224049571/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:52:12.200433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}